Company: LGNZZ
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000886163-25-000012
Chunk: 136

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-02-28
Form: 10-K
Item: Item 8
Chunk 136
---
 for the Agenus transaction(75,000)— — Cash paid for Apeiron acquisition, net of cash received(91,996)— — Cash paid for InvIOs investment(4,196)— — Net proceeds from Viking Share Collar and Viking Share Put7,123 — — Other— — (960)Net cash used in (provided by) investing activities(143,664)(11,682)163,624 

64

Cash flows from financing activities:Proceeds from common stock issuance, net of commissions and fees37,140 — — Net cash transferred to OmniAb at OmniAb Separation— — (1,840)Repayment at maturity/repurchase of 2023 Notes — (76,854)(260,949)Payments under finance lease obligations (25)(45)(54)Cash paid for transaction costs related to OmniAb Transactions— — (6,800)Cash paid for debt issuance costs (426)(949)— Proceeds from bond hedge settlement— — 202 Net proceeds from stock option exercises and ESPP65,588 22,448 3,232 Taxes paid related to net share settlement of equity awards(5,136)(4,547)(8,236)Payments to CVR Holders— — (1,545)Net cash provided by (used) in financing activities97,141 (59,947)(275,990)Effect of exchange rate changes on cash and cash equivalents(1,171)— — Net increase (decrease) in cash and cash equivalents49,353 (22,052)25,484 Cash and cash equivalents at beginning of year22,954 45,006 19,522 Cash and cash equivalents at end of year$72,307 $22,954 $45,006 Supplemental disclosure of cash flow informationInterest paid$263 $288 $1,428 Taxes paid$19,206 $8,770 $11,642 Acquisitions:           Fair value of tangible assets acquired, net of cash and restricted cash received$8,965 $17,887 $—            Goodwill— 3,709 —            Intangible assets— 10,700 —      Financial royalty assets106,156 — —            Liabilities assumed(23,